David A. Siegel Nuvalent, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Nuvalent, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 140,100 shares of NUVL stock, worth $10.8 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
140,100
Previous 152,200
7.95%
Holding current value
$10.8 Million
Previous $15.6 Million
29.56%
% of portfolio
0.03%
Previous 0.04%
Shares
3 transactions
Others Institutions Holding NUVL
# of Institutions
232Shares Held
59MCall Options Held
834KPut Options Held
490K-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.39 Billion34.87% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.36MShares$413 Million16.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.5MShares$347 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$233 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.62MShares$202 Million6.84% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.31B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...